- Home
- / Atea Pharmaceuticals
Atea Pharmaceuticals
Stock Price
$3.4
2024-10-29
Market Capitalization
$290.4 M
2024-10-29
Atea Pharmaceuticals Summary
Company Summary
- Overview
- Atea Pharmaceuticals is a biopharmaceutical company specializing in oral direct-acting antiviral therapies. It develops a platform of purine nucleos(t)ide prodrugs designed to target viral RNA polymerase. The company specializes in treating viral infections, such as SARS-CoV-2 and hepatitis C virus.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- Boston, MA, US | view all locations
- Website
- https://www.ateapharma.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Operating MetricsView all
Pre-Clinical Phase Products
2
Q2, 2020
Phase I Trials Products
2
Q2, 2020
Phase II Trials Products
2
Q2, 2020
LocationsView all
2 locations detected
Boston, MA HQ
United States
225 Franklin St #2100
Boston, MA
United States
125 Summer St
Atea Pharmaceuticals Financials
Summary Financials
- Net income (Q1, 2026)
- ($45.4M)
- Cash (Q1, 2026)
- $79.3M
- EBIT (Q1, 2026)
- ($48.0M)
- Enterprise value
- $211.7M